Jeil Pharma Holdings Inc (KRX:002620)
South Korea · Delayed Price · Currency is KRW 8,490.00
-100.00 (-1.16%)
At close: Apr 2, 2026
Jeil Pharma Holdings Revenue
In the year 2025, Jeil Pharma Holdings had annual revenue of 657.61B KRW, down -15.67%. Jeil Pharma Holdings had revenue of 154.43B in the quarter ending December 31, 2025, a decrease of -24.29%.
Revenue
657.61B
Revenue Growth
-15.67%
P/S Ratio
0.20
Revenue / Employee
17.77B
Employees
37
Market Cap
131.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 657.61B | -122.21B | -15.67% |
| Dec 31, 2024 | 779.82B | -24.22B | -3.01% |
| Dec 31, 2023 | 804.04B | 11.08B | 1.40% |
| Dec 31, 2022 | 792.96B | 30.40B | 3.99% |
| Dec 31, 2021 | 762.57B | 571.30M | 0.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ildong Holdings | 590.89B |
| HANDOK | 535.14B |
| Dongwha Pharm.Co.,Ltd | 496.39B |
| Whan In Pharm | 255.21B |
| Daihan Pharmaceutical | 208.61B |
| Kukje Pharma | 175.50B |
| CKD Bio | 159.93B |
| REYON Pharmaceutical | 149.34B |